Internal Medicine, Cardiovascular Disease · Saratoga Springs, NY
NPI
1609832096
Since 2006
Specialty
Internal Medicine, Cardiovascular Disease
Code 207RC0000X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
6 Care Ln
Saratoga Springs, NY, 12866
Phone (518) 587-7625
Groups this clinician bills Medicare through
Medicare paid, 2024
$288K
4,621 services
Medicare patients, 2024
766
Average age 75
Drug cost, 2024
$3.1M
9,671 prescriptions
Company payments, 2025
$243
From 6 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by David D Kandath was code 99214 (office e&m - established), 1,115 times for 608 patients. In total David D Kandath billed 4,621 services in 41 codes, and Medicare paid $288K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-05-11.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 1,115 | 608 | $85.84 | $96K |
| 93000 Electrocardiogram | Office | 722 | 576 | $9.80 | $7,073 |
| J2785 Injection, regadenoson, 0.1 mg | Office | 556 | 137 | $5.99 | $3,329 |
| A9502 Technetium tc-99m tetrofosmin, diagnostic, per study dose | Office | 314 | 163 | $116.70 | $37K |
| 93015 Electrocardiogram | Office | 282 | 269 | $45.53 | $13K |
| 93306 Echocardiography (TTE/TEE) | Office | 239 | 214 | $129.29 | $31K |
| 99215 Office E&M - Established | Office | 192 | 124 | $133.43 | $26K |
| 93298 External Electrocardiographic Monitoring | Office | 190 | 25 | $25.65 | $4,874 |
| 78452 Myocardial Perfusion Scan | Office | 178 | 178 | $277.74 | $49K |
| 93294 External Electrocardiographic Monitoring | Office | 160 | 50 | $21.36 | $3,417 |
| 93297 External Electrocardiographic Monitoring | Office | 109 | 15 | $18.03 | $1,965 |
| 93295 External Electrocardiographic Monitoring | Office | 66 | 19 | $26.41 | $1,743 |
| 93793 Care Management/Coordination | Office | 48 | 13 | $4.46 | $214 |
| 93280 External Electrocardiographic Monitoring | Office | 37 | 34 | $54.00 | $1,998 |
| 99205 Office E&M - New | Office | 35 | 35 | $159.41 | $5,579 |
By year: 2022 $292K for 4,196 services; 2023 $252K for 3,856 services; 2024 $288K for 4,621 services.
Lab tests billed to Medicare, 2023
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85610 Clinical Chemistry | 160 | 23 | $4.20 | $672 |
Medicare prescription drug claims, 2024
In 2024, the drug David D Kandath prescribed most often to Medicare patients was Rosuvastatin Calcium, with 1,628 prescriptions and refills. In total David D Kandath wrote 9,671 Medicare prescriptions that cost $3.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Rosuvastatin Calcium Generic | 1,628 | 4,504 | 525 | $32K |
| Ezetimibe Generic | 757 | 2,105 | 247 | $29K |
| Eliquis Apixaban | 692 | 1,585 | 201 | $899K |
| Carvedilol Generic | 370 | 1,009 | 124 | $3,328 |
| Spironolactone Generic | 341 | 876 | 119 | $2,840 |
| Clopidogrel Clopidogrel Bisulfate | 304 | 848 | 101 | $3,650 |
| Torsemide Generic | 296 | 715 | 110 | $4,534 |
| Ozempic Semaglutide | 277 | 405 | 65 | $376K |
| Losartan Potassium Generic | 250 | 682 | 83 | $2,563 |
| Pravastatin Sodium Generic | 244 | 712 | 84 | $3,862 |
| Jardiance Empagliflozin | 237 | 535 | 69 | $303K |
| Atorvastatin Calcium Generic | 236 | 674 | 80 | $2,778 |
| Atenolol Generic | 229 | 626 | 76 | $1,672 |
| Multaq Dronedarone Hcl | 220 | 534 | 66 | $393K |
| Xarelto Rivaroxaban | 177 | 438 | 52 | $236K |
Brand drugs: 2,309 claims; generic drugs: 7,362 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid David D Kandath $243 ($243 in general payments such as food, travel and fees) from 6 companies. The largest payer was Novartis Pharmaceuticals Corporation with $190.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.